Literature DB >> 1409466

[Toxoplasmosis in AIDS].

C Leport1, J S Remington.   

Abstract

Toxoplasmosis is one of the major opportunistic infections observed in France in 15 to 37 percent of HIV-infected patients. Its main manifestation is encephalitis. Other, less frequent manifestations are chorioretinitis, pneumonia or disseminated toxoplasmosis. The conventional treatment is a combination of pyrimethamine 50-75 mg/day and sulfadiazine 6-8 g/day. Acute therapy should be pursued for at least 3 weeks or until optimal response is achieved, i.e. 6 to 8 weeks in most cases. The pyrimethamine-clindamycin combination in doses of at least 2.4 g/day is a possible alternative. Other drugs are being studied, but there is still a need for new drugs active against the parasite, that could be used in humans. In HIV-infected patients treatment should be maintained lifelong to prevent relapses. Maintenance regimens use the same drugs as acute therapy but in lower doses. The main field of research is primary prophylaxis of toxoplasmosis in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409466

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients.

Authors:  J Durant; F Hazime; M Carles; J C Pechere; P Dellamonica
Journal:  Infection       Date:  1995       Impact factor: 3.553

2.  Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients.

Authors:  M Dupon; J Cazenave; J L Pellegrin; J M Ragnaud; A Cheyrou; I Fischer; B Leng; J Y Lacut
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Improvement and Evaluation of Loop-Mediated Isothermal Amplification for Rapid Detection of Toxoplasma gondii Infection in Human Blood Samples.

Authors:  Xi-Meng Sun; Yong-Sheng Ji; Xian-Yong Liu; Mei Xiang; Guang He; Li Xie; Jing-Xia Suo; Xun Suo
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.